Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mindy M. Hugo & Ipsita A. Banerjee. (2019) Development of new amphiphilic bio-organic assemblies for potential applications in iron-binding and targeting tumor cells. Soft Materials 17:1, pages 57-76.
Read now
Read now
Paula M. B. Pahl & Lawrence D. Horwitz. (2005) Cell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents. Cancer Investigation 23:8, pages 683-691.
Read now
Read now
David B Lovejoy & Des R Richardson. (2000) Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opinion on Investigational Drugs 9:6, pages 1257-1270.
Read now
Read now
Des R Richardson. (1999) The therapeutic potential of iron chelators. Expert Opinion on Investigational Drugs 8:12, pages 2141-2158.
Read now
Read now
Articles from other publishers (16)
Poonam Gupta, Pratibha Singh, Hriday S. Pandey, Pankaj Seth & Chinmay K. Mukhopadhyay. (2019) Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation. Biochimica et Biophysica Acta (BBA) - General Subjects 1863:3, pages 547-564.
Crossref
Crossref
Yu-Lin Chen, Xiaole Kong, Yuanyuan Xie & Robert C. Hider. (2018) The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron. Journal of Inorganic Biochemistry 180, pages 194-203.
Crossref
Crossref
Jian Wang, Song Wang, Pengcheng Sun, Fangqi Cao, Hui Li, Jing Sun, Min Peng, Wenbin Liu & Ping Shi. (2018) Iron depletion participates in the suppression of cell proliferation induced by lipin1 overexpression. Metallomics 10:9, pages 1307-1314.
Crossref
Crossref
JunGang Deng, Wei Chen & Hang Deng. (2016) Synthesis of Dipyridyl Ketone Isonicotinoyl Hydrazone Copper(II) Complex: Structure, Anticancer Activity and Anticancer Mechanism. Journal of Fluorescence 26:6, pages 1987-1996.
Crossref
Crossref
A Cacchione, A LeMaitre, D Valteau Couanet, E Benhamou, L Amoroso, N Simonnard & O Hartmann. (2008) Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. Bone Marrow Transplantation 42:7, pages 449-454.
Crossref
Crossref
V T Ho, C Revta & P G Richardson. (2007) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplantation 41:3, pages 229-237.
Crossref
Crossref
Paul G. Richardson. 2004. Stem Cell Transplantation for Hematologic Malignancies. Stem Cell Transplantation for Hematologic Malignancies
297
314
.
Martha Wadleigh, Vincent Ho, Parisa Momtaz & Paul Richardson. (2003) Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Current Opinion in Hematology 10:6, pages 451-462.
Crossref
Crossref
Paul V. Bernhardt, Lorraine M. Caldwell, Timothy B. Chaston, Piao Chin & Des R. Richardson. (2003) Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. JBIC Journal of Biological Inorganic Chemistry 8:8, pages 866-880.
Crossref
Crossref
Sheila A. Myer & Jamie Oliva. (2002) Severe Aplastic Anemia and Allogeneic Hematopoietic Stem Cell Transplantation. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 13:2, pages 169-191.
Crossref
Crossref
Des R. Richardson. 2002. Iron Chelation Therapy. Iron Chelation Therapy
231
249
.
Jiřıí Petrák & Daniel Vyoral. (2001) Detection of iron-containing proteins contributing to the cellular labile iron pool by a native electrophoresis metal blotting technique. Journal of Inorganic Biochemistry 86:4, pages 669-675.
Crossref
Crossref
Jin GaoDes R. Richardson. (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 98:3, pages 842-850.
Crossref
Crossref
David van Reyk, Shalom Sarel & Nicholas Hunt. (2000) Inhibition of in vitro lymphoproliferation by three novel iron chelators of the pyridoxal and salicyl aldehyde hydrazone classes. Biochemical Pharmacology 60:4, pages 581-587.
Crossref
Crossref
Douglas W. Wilmore, Paul R. Schloerb & Thomas R. Ziegler. (1999) Glutamine in the support of patients following bone marrow transplantation. Current Opinion in Clinical Nutrition and Metabolic Care 2:4, pages 323-327.
Crossref
Crossref
D.R. Richardson & P. Ponka. (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine 131:4, pages 306-315.
Crossref
Crossref